Mary Lange

TL;DR: In patients with persistently active rheumatoid arthritis, the combination of etanercept and methotrexate was safe and well tolerated and provided significantly greater clinical benefit than metotrexate alone.

TL;DR: In a phase II study, etanercept (recombinant human tumor necrosis factor receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in rheumatoid arthritis over 3 months as discussed by the authors.

TL;DR: This study sought to define further the clinical activity of etanercept over a longer treatment period and to establish a simplified dosing schema for rheumatoid arthritis.

TL;DR: Children with severe, longstanding, methotrexate-resistant polyarticular JRA demonstrated sustained clinical improvement with >2 years of continuous etanercept treatment.

TL;DR: PIXY321 decreased the incidence and duration of FAC-induced grade 3 and 4 neutropenia in cycles 1 and 2 and significantly shortened the time to hematologic recovery in all cycles, however, it produced more systemic toxicity as well as thrombocytopenIA in cycles3 and 4.